With the nation’s opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned ‘the lion’s share’ of their Medicare income exclusively from urine drug screens.
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
A Kaiser Health News analysis finds that the portion of federal marketplace plans requiring people to pay a third or more of the cost of specialty drugs have jumped from 37 to 63 percent since 2014. California has greater protections to limit consumer costs.